Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer - Top-Institutions - MDSpire

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

  • By

  • Chuan Angel Lu

  • Changchuan Jiang

  • Andrew Z. Wang

  • Tian Zhang

  • May 29, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Oncology

  • #2

    Massachusetts General Brigham Health System
    Massachusetts General Brigham Health System

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #4

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

  • #5

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

  • by Chuan Angel Lu, Changchuan Jiang, Andrew Z. Wang, Tian Zhang

  • May 29, 2026

Related Content

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min
Late radiation necrosis following stereotactic radiosurgery after COVID-19 vaccination: a case report and hypothesis of immune-mediated inflammatory activation

Editorial: Molecular pathways and signaling molecules in cancer therapy: advances and innovations